Tivic Health Systems, Inc. (TIVC) Q4 2025 Earnings Call Prepared Remarks Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a strategic shift towards immunotherapy and government partnerships, which is promising. However, regulatory, competitive, and financial risks are significant, particularly with increased expenses and reliance on government funding. The Q&A section did not provide additional clarity, leaving uncertainties unresolved. While there are positive developments, such as internal manufacturing capabilities and increased cash reserves, these are offset by the risks and financial challenges. Therefore, the stock price is likely to remain stable in the short term, resulting in a neutral sentiment.
Key Financial Performance
Operating Expenses $7.9 million compared to $4.5 million for the year ended December 31, 2024. The increase was primarily due to the introduction of the biopharma business in February 2025, when the company licensed certain biologics and increased our headcount and professional services to support the development of Entolimod. Additionally, in December 2025, we formed Velocity Bioworks and hired 45 employees to support the CDMO operation.
Loss from Discontinued Operations Decreased from $1.2 million to $900,000 for the year ended December 31, 2025. Discontinued operations included all activities related to the consumer product business that Tivic exited in 2025. During 2025, we reduced advertising and marketing spend related to the business to focus resources on our TLR5 program.
Cash and Cash Equivalents $12.6 million at December 31, 2025, compared with $2 million at December 31, 2024. The increase was due to the $16.3 million financing through a securities purchase agreement and remaining funds from planned tranches of our preferred purchase agreement.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Entolimod and Entolasta: Lead candidates in the oncology supportive care market, targeting radiation and chemotherapy side effects. Positioned to disrupt the $15 billion market, expected to grow to $20 billion by the 2030s. Entolimod is the only known therapy protecting bone marrow and gastrointestinal tract from radiation and chemotherapy damage.
Oncology supportive care market: A multibillion-dollar market with significant unmet needs. Approximately 60% of cancer patients undergoing radiation or chemotherapy could benefit from Tivic's therapies.
Biodefense sector: Entolimod positioned as a stockpiling agent for the National Strategic Stockpile, addressing acute radiation syndrome with FDA Fast Track and orphan drug designation.
Velocity Bioworks: Acquired in December 2025, this in-house manufacturing capability reduces development timelines and costs for Entolimod, ensures supply chain control, and serves as a revenue driver by targeting early-stage biologics manufacturing gaps.
Discontinuation of consumer device business: Exited the ClearUP device business and noncore neuromodulation programs to focus resources on high-value biotherapeutic opportunities.
Transition to immunotherapy biopharmaceutical company: Shifted focus to immunotherapy, anchored by the TLR5 platform, and discontinued legacy consumer device operations.
Government partnerships: Engaged with U.S. and international governments to secure funding and partnerships for radiation protection solutions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Competition: The oncology supportive care market is mature and faces pricing pressure from biosimilars, which could impact the competitive positioning and profitability of Tivic's products.
Regulatory and Development Risks: Entolimod is still in the development phase, with physician-sponsored trials and Phase IIb studies yet to be initiated. Regulatory hurdles and proving efficacy in clinical trials pose significant risks.
Financial Sustainability: The company reported increased operating expenses ($7.9 million in 2025 compared to $4.5 million in 2024) due to the transition to biopharma and the establishment of Velocity Bioworks. This raises concerns about financial sustainability and the ability to manage costs effectively.
Supply Chain and Manufacturing Risks: While the acquisition of Velocity Bioworks aims to internalize manufacturing and control the supply chain, scaling operations and ensuring consistent quality remain challenges.
Dependence on Government Funding: The company is actively seeking non-dilutive government funding for Entolimod's development in the biodefense sector. Dependence on such funding introduces uncertainty and potential delays.
Debt Obligations: The $16.3 million debt instrument and associated financial obligations could strain the company's financial resources, especially if revenue generation is delayed.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Oncology Supportive Care Market: The company is targeting the oncology supportive care market, which is expected to grow from $15 billion to $20 billion by the 2030s. Tivic plans to initiate physician-sponsored trials for Entolimod this year, aiming to provide proof of efficacy and a basis for Phase IIb studies.
Entolimod Development and Market Positioning: Entolimod is positioned to disrupt established markets due to its ability to prevent programmed cell death in vital tissues. It is being advanced into large market clinical indications, starting with neutropenia. The company is also pursuing opportunities in the biodefense sector, with Entolimod being considered for the National Strategic Stockpile as a treatment for acute radiation syndrome.
Velocity Bioworks and Manufacturing Capabilities: The acquisition of Velocity Bioworks enables Tivic to internalize manufacturing, reducing development timelines and costs for Entolimod. The facility is expected to scale production as needed and serve as a revenue driver by targeting early-stage biologics manufacturing for Phase I and II biotech firms. Full utilization could result in a self-sustaining, cash flow-positive operation.
Government Partnerships and Funding: Tivic is actively engaging with U.S. government agencies like BARDA and NIAID to secure non-dilutive funding for Entolimod's development as a biodefense agent. The drug's dual-use capability for prophylactic and post-exposure treatment makes it a strong candidate for government stockpiling.
Financial Position and Future Funding: The company has $12.6 million in cash and cash equivalents as of December 31, 2025, with an additional $6 million in planned tranches and the ability to raise up to $50 million through a common stock purchase agreement over the next two years. These funds will support GMP manufacturing validation for Entolimod and the ramp-up of CDMO operations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
CDMO
CFO Principal
Financial Principal
Phase
Principal Accounting
Principal Financial
ability
agent
biologics
bone marrow
capability
care market
consumer device
employee
future
immunotherapy
journey
oncology care
operation
party
platform
preparedness
program asset
purchase agreement
radiation chemo
radiation chemotherapy
resource
side effect
stock
supply chain
term value
tissue
update
vision
year
TIVC Transcript
Tivic Health Systems, Inc. (TIVC) Q4 2025 Earnings Call Prepared Remarks Transcript
Unknown3-25
The earnings call reflects a strategic shift towards immunotherapy and government partnerships, which is promising. However, regulatory, competitive, and financial risks are significant, particularly with increased expenses and reliance on government funding. The Q&A section did not provide additional clarity, leaving uncertainties unresolved. While there are positive developments, such as internal manufacturing capabilities and increased cash reserves, these are offset by the risks and financial challenges. Therefore, the stock price is likely to remain stable in the short term, resulting in a neutral sentiment.
Tivic Health Systems, Inc. (TIVC) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call highlights significant challenges: declining revenue due to reduced marketing, increased operating expenses, and substantial net losses. Despite efforts to pivot towards immunotherapeutics, financial constraints and regulatory hurdles pose risks. The cash position is weak, raising concerns about sustainability. While gross margins improved, the lack of positive catalysts like new partnerships or strong guidance suggests a negative outlook. The absence of clarity in management responses during the Q&A further exacerbates uncertainties, likely leading to a negative stock price reaction.
Tivic Health Systems, Inc. (NASDAQ:TIVC) Q1 2025 Earnings Call Transcript
Unknown5-17
The earnings call reveals a promising strategic shift with new product acquisitions and improved financials, including increased revenue and reduced net loss. However, the lack of a shareholder return plan, competitive pressures, regulatory and supply chain risks, and unclear guidance on key programs like VNS and Entolimod's BLA filing temper the positive aspects. The absence of a share buyback program and concerns raised in the Q&A further add to the neutral sentiment. Without a market cap, the stock's reaction is uncertain, but the overall sentiment suggests limited short-term movement.
Tivic Health Systems Inc. (TIVC) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call highlights significant challenges, including a drastic revenue decline due to reduced advertising, a flat net loss, and dwindling cash reserves. Despite strategic moves like securing an equity line and strategic financing, the financial risks and regulatory hurdles, along with competitive pressures, overshadow potential gains. The market may react negatively to these uncertainties, particularly given the lack of clear guidance and the risks associated with transitioning to a biopharmaceutical focus.
TIVC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
